In Mounjaro , 4.6% of people with anti-tirzepatide antibodies had injection site reactions, compared with 0.7% without antibodies
The most commonly reported effects are mild injection-site irritation, short-term fatigue during TB-500 loading, and occasional headache
To view or add a comment, sign in Zealand Pharma's Obesity Drug Trial Results Lead to Significant Share Drop obesity drug Zealand Pharma obesity Zealand Pharma's shares fell by 30% following disappointing results from a trial of its obesity drug, which did not meet expectations
With monthly treatment expenses reaching about US$ 1,000, many patients find these drugs prohibitively expensive, particularly those without comprehensive insurance coverage
Their success will depend on striking the right balance between biological complexity, therapeutic efficacy, patient convenience, and manufacturing feasibilitya formidable but exciting scientific frontier
doi: 10.1080/19476337.2016.1266033 22